<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387672</url>
  </required_header>
  <id_info>
    <org_study_id>062011</org_study_id>
    <nct_id>NCT01387672</nct_id>
  </id_info>
  <brief_title>Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study</brief_title>
  <acronym>NABT;NABT-B</acronym>
  <official_title>Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Pacific Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: NABT: To compare five widely available nitrate formulations: (1) 15 of nitroglycerin
      (NTG) ointment, (2) 0.3 mg and (3) 0.6 mg of sublingual NTG, (4) 20 mg of isosorbide
      mononitrate (an oral tablet), and (5) 160 mg of glycerol trinitrate (a patch), for their
      efficacy on markers of bone formation and resorption and for the incidence and severity of
      headache they cause.

      Hypothesis: There is one ideal nitrate preparation which balances the clinical efficacy in
      bone remodeling against the common side effect of headache.

      NABT-B: To determine if nitrates affect markers of bone formation (serum BALP and P1NP) and
      resorption (serum CTX and urine NTX) in women who have recently discontinued treatment with
      alendronate, risedronate or zoledronate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Turnover Markers</measure>
    <time_frame>3 months</time_frame>
    <description>Markers of Bone Formation:
Serum Procollagen type 1 amino- terminal propeptide (P1NP)
Serum Osteocalcin (OC)
Serum Bone-specific alkaline phosphatase (BALP)
Markers of Bone Resorption:
- Serum C-telopeptides of collagen cross-links (CTX)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>Run-in phase - 2 days</time_frame>
    <description>Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from &quot;0&quot; to &quot;10&quot;. A vertical line marked at &quot;0&quot; means no headache (score recorded = &quot;0&quot;), a vertical line marked at &quot;10&quot; means a terrible headache (score recorded = &quot;10&quot;).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Nitrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin Ointment 2% USP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitro-Dur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin Extended Release Patch 160mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrostat 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin 0.3mg Sublingual Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrostat 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin 0.6mg Sublingual Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISMO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide Mononitrate 20mg Oral Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrates (NABT Main trial)</intervention_name>
    <description>nitroglycerin; isosorbide mononitrate</description>
    <arm_group_label>Nitrol</arm_group_label>
    <arm_group_label>Nitro-Dur</arm_group_label>
    <arm_group_label>Nitrostat 1</arm_group_label>
    <arm_group_label>Nitrostat 2</arm_group_label>
    <arm_group_label>ISMO</arm_group_label>
    <other_name>NABT-B Sub-Study: Nitroglycerin Ointment 2%: 15mg of NTG ointment for a 3 month period</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ointment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        NABT:

          -  Women aged 50 years and older whose last menstrual period occurred at least 3 years
             ago

          -  Women without a uterus will be eligible after age 55

        NABT-B:

          -  Women aged 50 years and older whose last menstrual period occurred at least 3 years
             ago

          -  Women without a uterus will be eligible after age 55

          -  Previously treated with alendronate but stopped within 2 years of study commencement;
             or previously treated with risedronate but stopped within 1 year of study
             commencement; or previously treated with zoledronate.

        Exclusion Criteria:

        NABT:

          -  A previous fracture of the hip, wrist, spine or ankle within the last 3 months; or a
             diagnosis of osteoporosis;

          -  A history of bone disorders such as hyperparathyroidism or Paget's disease;

          -  Treatment within 12 months of study entry with any agent that may influence bone
             metabolism including any hormone, anti-estrogen or raloxifene and prednisone
             (equivalent to 5 mg/d for 12 months or greater);

          -  Treatment with any antiresorptive agent, including alendronate, risedronate,
             etidronate or denosumab use for at least four weeks within the last three years;

          -  Previous treatment with intravenous zoledronate or parathyroid hormone;

          -  Current treatment with nitrates;

          -  A history of migraine headaches;

          -  A history of angina or cardiovascular disease;

          -  Inability to give informed consent;

          -  Hypersensitivity to nitroglycerin.

        NABT-B:

          -  A previous fracture of the hip, wrist, spine or ankle; or a self-reported diagnosis of
             osteoporosis;

          -  A history of bone disorders such as hyperparathyroidism or Paget's disease;

          -  Treatment within 12 months of study entry with any agent that may influence bone
             metabolism including any hormone, anti-estrogen or raloxifene and prednisone
             (equivalent to 5 mg/d for 12 months or greater);

          -  Treatment with etidronate or denosumab use for at least four weeks within the last
             three years and any previous treatment with parathyroid hormone;

          -  Current treatment with nitrates;

          -  A history of migraine headaches;

          -  A history of angina or cardiovascular disease;

          -  Inability to give informed consent;

          -  Hypersensitivity to nitroglycerin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie A Jamal, MD,PhD,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Research Institute/Women's College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's College Research Institute/Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA. 2011 Feb 23;305(8):800-7. doi: 10.1001/jama.2011.176. Retraction in: Eastell R, Hamilton CJ, Cummings SR. JAMA. 2016 Jan 26;315(4):418-9.</citation>
    <PMID>21343579</PMID>
  </reference>
  <reference>
    <citation>Jamal SA, Goltzman D, Hanley DA, Papaioannou A, Prior JC, Josse RG. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2009 May;20(5):737-44. doi: 10.1007/s00198-008-0727-7. Epub 2008 Sep 18. Retraction in: Osteoporos Int. 2016 Dec 1;:.</citation>
    <PMID>18800179</PMID>
  </reference>
  <reference>
    <citation>Jamal SA, Cummings SR, Hawker GA. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res. 2004 Sep;19(9):1512-7. Epub 2004 Jul 26.</citation>
    <PMID>15312252</PMID>
  </reference>
  <reference>
    <citation>Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998 Nov;13(11):1755-9.</citation>
    <PMID>9797485</PMID>
  </reference>
  <reference>
    <citation>Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009 Sep;94(9):3356-64. doi: 10.1210/jc.2008-2225. Epub 2009 Jun 23.</citation>
    <PMID>19549739</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <results_first_submitted>February 17, 2015</results_first_submitted>
  <results_first_submitted_qc>May 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2015</results_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Sophie Jamal</investigator_full_name>
    <investigator_title>Associate Professor/Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>postmenopausal</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>bone turnover</keyword>
  <keyword>nitrate</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Initial run-in period-subjects received, in random order, each of the 5 nitrate formulations for 2 days with a 2 day wash out period between formulations. There were 265 subjects enrolled in the run-in phase of the study. Out of those, 229 subjects entered the treatment phase of the study, where they were randomized to one of the 6 treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ISMO - Treatment Arm 1</title>
          <description>Isosorbide Mononitrate 20mg Oral Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="P2">
          <title>Patch (Nitro-Dur) - Treatment Arm 2</title>
          <description>Nitroglycerin Extended Release Patch 160mg
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="P3">
          <title>Ointment (Nitrol) - Treatment Arm 3</title>
          <description>Nitroglycerin Ointment 2% USP
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="P4">
          <title>0.3 Sublingual (Nitrostat 1) - Treatment Arm 4</title>
          <description>Nitroglycerin 0.3mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="P5">
          <title>0.6 Sublingual (Nitrostat 2) - Treatment Arm 5</title>
          <description>Nitroglycerin 0.6mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="P6">
          <title>Placebo Ointment - Treatment Arm 6</title>
          <description>Placebo Ointment
Nitrates (NABT Main trial)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ISMO - Treatment Arm 1</title>
          <description>Isosorbide Mononitrate 20mg Oral Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="B2">
          <title>Patch (Nitro-Dur) - Treatment Arm 2</title>
          <description>Nitroglycerin Extended Release Patch 160mg
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="B3">
          <title>Ointment (Nitrol) - Treatment Arm 3</title>
          <description>Nitroglycerin Ointment 2% USP
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="B4">
          <title>0.3 Sublingual (Nitrostat 1) - Treatment Arm 4</title>
          <description>Nitroglycerin 0.3mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="B5">
          <title>0.6 Sublingual (Nitrostat 2) - Treatment Arm 5</title>
          <description>Nitroglycerin 0.6mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="B6">
          <title>Placebo Ointment - Treatment Arm 6</title>
          <description>Placebo Ointment
Placebo: Placebo ointment Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="38"/>
            <count group_id="B6" value="37"/>
            <count group_id="B7" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover Markers</title>
        <description>Markers of Bone Formation:
Serum Procollagen type 1 amino- terminal propeptide (P1NP)
Serum Osteocalcin (OC)
Serum Bone-specific alkaline phosphatase (BALP)
Markers of Bone Resorption:
- Serum C-telopeptides of collagen cross-links (CTX)</description>
        <time_frame>3 months</time_frame>
        <population>One subject from the Treatment Arm 3 had outlier bone turnover markers values and was excluded from the analysis. Total number of subjects analyzed in Treatment Arm 3 was therefore 32.</population>
        <group_list>
          <group group_id="O1">
            <title>ISMO - Treatment Arm 1</title>
            <description>Isosorbide Mononitrate 20mg Oral Tablet
Nitrates (NABT Main trial)</description>
          </group>
          <group group_id="O2">
            <title>Patch (Nitro-Dur) - Treatment Arm 2</title>
            <description>Nitroglycerin Extended Release Patch 160mg
Nitrates (NABT Main trial)</description>
          </group>
          <group group_id="O3">
            <title>Ointment (Nitrol) - Treatment Arm 3</title>
            <description>Nitroglycerin Ointment 2% USP
Nitrates (NABT Main trial)</description>
          </group>
          <group group_id="O4">
            <title>0.3 Sublingual (Nitrostat 1) - Treatment Arm 4</title>
            <description>Nitroglycerin 0.3mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
          </group>
          <group group_id="O5">
            <title>0.6 Sublingual (Nitrostat 2) - Treatment Arm 5</title>
            <description>Nitroglycerin 0.6mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
          </group>
          <group group_id="O6">
            <title>Placebo Ointment - Treatment Arm 6</title>
            <description>Placebo Ointment
Placebo: Placebo ointment Nitrates (NABT Main trial)</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Markers</title>
          <description>Markers of Bone Formation:
Serum Procollagen type 1 amino- terminal propeptide (P1NP)
Serum Osteocalcin (OC)
Serum Bone-specific alkaline phosphatase (BALP)
Markers of Bone Resorption:
- Serum C-telopeptides of collagen cross-links (CTX)</description>
          <population>One subject from the Treatment Arm 3 had outlier bone turnover markers values and was excluded from the analysis. Total number of subjects analyzed in Treatment Arm 3 was therefore 32.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P1NP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.627" spread="16.191"/>
                    <measurement group_id="O2" value="-0.405" spread="20.289"/>
                    <measurement group_id="O3" value="-4.297" spread="16.236"/>
                    <measurement group_id="O4" value="-6.126" spread="16.093"/>
                    <measurement group_id="O5" value="2.941" spread="36.843"/>
                    <measurement group_id="O6" value="-1.635" spread="16.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.244" spread="12.049"/>
                    <measurement group_id="O2" value="3.796" spread="33.601"/>
                    <measurement group_id="O3" value="-4.481" spread="14.823"/>
                    <measurement group_id="O4" value="1.046" spread="21.818"/>
                    <measurement group_id="O5" value="1.033" spread="17.931"/>
                    <measurement group_id="O6" value="4.247" spread="22.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.023" spread="11.824"/>
                    <measurement group_id="O2" value="-0.541" spread="20.738"/>
                    <measurement group_id="O3" value="-7.426" spread="11.056"/>
                    <measurement group_id="O4" value="-7.000" spread="19.011"/>
                    <measurement group_id="O5" value="-3.686" spread="17.435"/>
                    <measurement group_id="O6" value="-1.648" spread="21.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.844" spread="26.084"/>
                    <measurement group_id="O2" value="-1.025" spread="32.163"/>
                    <measurement group_id="O3" value="-9.699" spread="27.299"/>
                    <measurement group_id="O4" value="-0.666" spread="37.945"/>
                    <measurement group_id="O5" value="-1.380" spread="52.248"/>
                    <measurement group_id="O6" value="-1.783" spread="28.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache</title>
        <description>Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from &quot;0&quot; to &quot;10&quot;. A vertical line marked at &quot;0&quot; means no headache (score recorded = &quot;0&quot;), a vertical line marked at &quot;10&quot; means a terrible headache (score recorded = &quot;10&quot;).</description>
        <time_frame>Run-in phase - 2 days</time_frame>
        <population>The mean headache score considering all subjects in each of the treatment/formulation group was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Phase</title>
            <description>During the run-in phase subjects received, in random order, each of the 5 nitrate formulations for 2 days with a 2 day wash out period between formulations. The severity of headaches was recorded, by subjects, upon awakening, every day during the run in phase using a visual analog scale (VAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Headache</title>
          <description>Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from &quot;0&quot; to &quot;10&quot;. A vertical line marked at &quot;0&quot; means no headache (score recorded = &quot;0&quot;), a vertical line marked at &quot;10&quot; means a terrible headache (score recorded = &quot;10&quot;).</description>
          <population>The mean headache score considering all subjects in each of the treatment/formulation group was calculated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ISMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ointment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.3 Sublingual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.6 Sublingual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Adverse Events are reported for the 3 months treatment phase of the study, once the patients were randomized to a specific treatment arm (ISMO - Arm 1; Patch - Arm 2; Ointment - Arm 3; 0.3 Sublingual - Arm 4; 0.6 Sublingual - Arm 5 or Placebo - Arm 6)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISMO - Treatment Arm 1</title>
          <description>Isosorbide Mononitrate 20mg Oral Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="E2">
          <title>Patch (Nitro-Dur) - Treatment Arm 2</title>
          <description>Nitroglycerin Extended Release Patch 160mg
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="E3">
          <title>Ointment (Nitrol) - Treatment Arm 3</title>
          <description>Nitroglycerin Ointment 2% USP
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="E4">
          <title>0.3 Sublingual (Nitrostat 1) - Treatment Arm 4</title>
          <description>Nitroglycerin 0.3mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="E5">
          <title>0.6 Sublingual (Nitrostat 2) - Treatment Arm 5</title>
          <description>Nitroglycerin 0.6mg Sublingual Tablet
Nitrates (NABT Main trial)</description>
        </group>
        <group group_id="E6">
          <title>Placebo Ointment- Treatment Arm 6</title>
          <description>Placebo Ointment
Placebo: Placebo ointment Nitrates (NABT Main trial)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Global Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="38"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="38"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" events="112" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sophie Jamal</name_or_title>
      <organization>Womens' College Hospital</organization>
      <phone>416-351-3732 ext 2873</phone>
      <email>sophie.jamal@wchospital.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

